Jan. 8 at 5:03 PM
VolitionRx reported breakthrough results for its Nu.Q® Vet Feline cancer screening test, showing high accuracy in detecting feline lymphoma, the most common cancer in cats. The blood-based test achieved 100% specificity, with no false positives, and detected more than 80% of feline lymphoma cases.
The company believes the assay could become the world’s first simple and affordable liquid biopsy for feline cancer, addressing a major unmet need in veterinary medicine where diagnosis often relies on invasive biopsies or costly imaging. Volition sees significant commercial potential, given the large and aging cat population and the high lifetime cancer risk.
Executives said the successful results build on the international launch of its canine cancer test and support the goal of making cancer screening part of routine annual pet checkups. Volition also noted that publication of the study could trigger a
$5 million contractual payment.
$VNRX